Exelixis heads into the back half of August with short sellers retreating and the Street divided on whether the recent pullback has created a buying opportunity — or simply confirmed the stock's ceiling.
The positioning story is the more interesting one right now. Short interest has fallen nearly 5% on the week to 10.6% of free float, unwinding a buildup that peaked around 30 million shares in early August. That decline follows the Q2 earnings-day drop of nearly 7% on August 5, after which shorts appear to have taken profits rather than pressed the thesis. Borrow is effectively free — cost to borrow runs at just 0.38% — and the lending pool is anything but tight, with availability at 1,064% of current short interest. That means there are roughly ten shares available to lend for every one already borrowed, removing any squeeze dynamic entirely. The put/call ratio of 1.32 sits modestly above its 20-day average of 1.27, a mildly defensive lean but well within normal range for this name. Taken together, the positioning picture reads as cautious rather than aggressive: shorts are covering, not building, and options hedgers are not particularly alarmed.
What the Street is paying for remains the central debate. The consensus is a unanimous hold — all 12 rated analysts are neutral, with the mean price target of $53 essentially at the current price of $53.12. BMO Capital initiated coverage Wednesday at Market Perform with a $54 target, in line with that bland consensus. Truist cut its target to $52 after earnings, while Stifel nudged its hold target up to $51 from $47 — a pair of moves that illustrate the fork: Truist sees the print as a mild negative, Stifel sees the valuation as slightly less stretched. Morgan Stanley raised its target to $53 in late July ahead of the report. The Street collectively moved targets higher through July, then paused or trimmed after results. The bull case rests on Cabometyx commercial momentum and Phase 3 pipeline catalysts, particularly the STELLAR-316 and STELLAR-304 trials. The bear case points to intense competition in its oncology segments and lingering concern about the stock's valuation at a PE near 13x after a strong run — EV/EBITDA has eased modestly to 9.4x over the past month, though P/B has slipped to 3.98x as the stock drifted lower. The forward EPS growth score ranks in just the 30th percentile, signalling that the easy earnings-upgrade cycle has done much of its work.
Insider activity is the one data point that cuts clearly in one direction. The 90-day net insider flow is a net sell of roughly $19.3 million across multiple executives, including a $6.6 million disposal by CEO Michael Morrissey in May and a $1.7 million sale by CFO Christopher Senner. Director Mary Beckerle sold a further $527,000 on August 10, the most recent transaction on record. None of these moves are unusual in isolation for a stock that has climbed 28%-plus year-to-date, and significance scores are low. But the pattern is consistent: no insider has used the current price level to add shares.
The most recent earnings print reinforces the cautious tone. The August 5 Q2 release triggered a 6.8% one-day drop and an additional 3.3% over the following week — a total five-day move of roughly minus 10%. The prior event in late July carried a much smaller reaction, down less than 1% on the day. The next scheduled print is November 3. Among correlated peers, NBIX fell 4.8% on the week while EBS gained 4.7%, illustrating the wide dispersion within the group even as EXEL posted a solid 3.5% week.
The ORTEX short score has drifted lower through August — from 65.1 on August 5 to 63.7 today — consistent with the ongoing short covering. The key variable to track is whether that covering continues through the STELLAR trial readout timeline, or whether shorts rebuild at a price level the Street collectively considers full.
See the live data behind this article on ORTEX.
Open EXEL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
